Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022; 24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022; 24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022; 24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022; 24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”
Dr Mustfa K. Manzur joins Ethics Talk to discuss his article, coauthored with Drs Sharon Griswold and Wendy Dean: "What Should Clinicians Do When Health Services Are Improperly Billed in Their Names?"